Stem cell sources for clinical islet transplantation in type 1 diabetes: Embryonic and adult stem cells

2006 ◽  
Vol 67 (4) ◽  
pp. 909-913 ◽  
Author(s):  
Helena Miszta-Lane ◽  
Mohammadreza Mirbolooki ◽  
A.M. James Shapiro ◽  
Jonathan R.T. Lakey
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Stem Cell ◽  
Islet Transplantation ◽  
Adult Stem Cells ◽  
Clinical Islet Transplantation ◽  
Cell Sources

scholarly journals Challenges in stem cell-derived islet replacement therapy can be overcome

2021 ◽  
Vol 30 ◽  
pp. 096368972110453
Author(s):  
Midhat H. Abdulreda ◽  
Per-Olof Berggren
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Stem Cell ◽  
Anterior Chamber ◽  
Replacement Therapy ◽  
Islet Transplant ◽  
Clinical Islet Transplantation ◽  
The Status ◽  
Transplant Site

In this Commentary, we echo the conclusions of a recent review titled “ The promise of stem cell-derived islet replacement therapy,” which highlighted recent advances in producing glucose responsive “islets” from stem cells and the benefits of their use in islet transplant therapy in type 1 diabetes (T1D). The review also outlined the status of clinical islet transplantation and the challenges that have prevented it from reaching its full therapeutic promise. We agree with the conclusions of the review and suggest that the identified challenges may be overcome by using the eye anterior chamber as an islet transplant site. We anticipate that the combination of stem cell-derived islets and intraocular transplant could help this promising T1D therapy reach full fruition.

Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes

2009 ◽  
Vol 35 (2) ◽  
pp. 85-93 ◽  
Author(s):  
L. Vija ◽  
D. Farge ◽  
J.-F. Gautier ◽  
P. Vexiau ◽  
C. Dumitrache ◽  
...  
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy

scholarly journals The Future of Clinical Islet Transplantation in the United States

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Michael F Knoll ◽  
Carmela A Knoll ◽  
Rita Bottino ◽  
Massimo Trucco ◽  
Suzanne Bertera ◽  
...  
Keyword(s):  
Quality Of Life ◽  
United States ◽  
Type 1 Diabetes ◽  
Islet Transplantation ◽  
Drug Administration ◽  
The United States ◽  
Clinical Islet Transplantation ◽  
The World

Clinical islet transplantation was first realized over four decades ago at the University of Minnesota. Autologous islet transplantation is now widely recognized as a treatment to prevent diabetes in patients after pancreas excision and is offered at major transplant centers throughout the United States and the world. Type 1 diabetes represents a much larger demographic in which islet transplantation may benefit patients. Allogeneic islet transplantation can now offer similar outcomes to pancreas transplantation in a subset of patients with labile type 1 diabetes with less risk than whole organ transplantation. It is recognized as a standard of care in nations around the world but not in the United States, despite the important developmental role US scientists and physicians have played. Early reports of islet transplantation focused on insulin independence that proved to diminish over time. However, regardless of insulin status, islet transplantation provides benefits ranging from improved quality of life to reduction in diabetic complications. A National Institutes of Health sponsored multi-center Phase 3 Clinical Trial (CIT-07) demonstrated safety and efficacy, although the Food and Drug Administration chose to consider islets as a biologic that requires licensure, which makes offering the procedure in the clinic very challenging. Until regulations can be brought into communion with international standards, allogeneic islet transplantation in the United States is unlikely to match international levels of success and once promising programs are left to wither on the vine. Food and Drug Administration approval would open the door for third party medical reimbursement and allow many patients the opportunity to enjoy better health and quality of life. Establishment of clinical islet transplantation for type 1 diabetes would lead to optimizations in procedures making it more efficacious and cost effective while offering support for ongoing islet xenotransplantation studies that could bring islet transplantation to even more patients.

Clinical islet transplantation in type 1 diabetes mellitus: results of Australia's first trial

2006 ◽  
Vol 184 (5) ◽  
pp. 221-225 ◽  
Author(s):  
Philip J O’Connell ◽  
Wayne J Hawthorne ◽  
Brian J Nankivell ◽  
Anita T Patel ◽  
Stacey N Walters ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Islet Transplantation ◽  
Clinical Islet Transplantation

scholarly journals Stem Cell Therapy in Treating Type 1 Diabetes Mellitus –Potential and Ethical Issues.

2021 ◽  
Author(s):  
Nursuaidah Abdullah ◽  
Marjanu Hikmah Elias
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Cell Transplant ◽  
Exogenous Insulin ◽  
Hematopoietic Stem ◽  
Wide Range

Type 1 diabetes (T1D) is a deficiency in insulin production which is mainly due to loss of ?-cell pancreatic islets. Patients with T1D need to be given exogenous insulin regularly. While improvements in the delivery of insulin and glucose monitoring methods have been effective in improving patient safety, insulin therapy is not a cure and is often associated with complications and debilitating hypoglycaemic episodes. Meanwhile, pancreas or islet transplantation as a gold standard only promises temporary freedom from exogenous insulin and suffers from issues of its own. Stem cell therapy may provide a more permanent solution, given stem cells’ immunomodulatory characteristics and ability to self-renew and distinguish into specific cells. In this sense, the therapeutic potentials of stem cells are addressed in this study. These stem cells cover a wide range of treatments for T1D including embryonic stem cells, induced pluripotent stem cells, bone-marrow derived hematopoietic stem cells and multipotent mesenchymal stromal cells. The challenges faced by the current stem cell transplant in T1D treatment and Islamic viewpoints regarding ethics in stem cell research and therapy are also discussed. In conclusion, stem cell therapy offers a safe and efficient alternative treatment for T1D. However, besides the fatwa from Fatwa Committee of Selangor, the lack of Malaysian stem cells ethics should be further addressed.

scholarly journals Spleen, as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells

2018 ◽  
Author(s):  
Naoaki Sakata ◽  
Gumpei Yoshimatsu ◽  
Shohta Kodama
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Clinical Success ◽  
Severe Diabetes ◽  
Clinical Islet Transplantation ◽  
Long Time ◽  
Optimal Site

In this review, we show the unique potential of spleen as an optimal site for islet transplantation and a source of mesenchymal stem cells. Islet transplantation is a cellular replacement therapy to treat severe diabetes mellitus, but its clinical outcome is unsatisfactory at present. One factor in clinical success of this therapy is selection of the most appropriate transplantation site. The spleen has been studied for a long time as a candidate site for islet transplantation. Its advantages include physiological insulin drainage and regulation of immunity. Recently it has also been shown that the spleen contributes to the regeneration of transplanted islets. The efficacy of transplantation is not as high as that obtained with intraportal transplantation, which is the current representative method of clinical islet transplantation. Safer and more effective methods of islet transplantation need to be established before the spleen can be effectively used in the clinic. Spleen also has an interesting aspect as a mesenchymal stem cell reservoir. The splenic mesenchymal stem cells contribute to tissue repair in damaged tissue, and thus, the infusion can be a promising therapy for autoimmune diseases, including type 1 diabetes mellitus and Sjogren’s syndrome.

scholarly journals Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells

2016 ◽  
Vol 2016 ◽  
pp. 1-22 ◽  
Author(s):  
Nadine E. Rekittke ◽  
Meidjie Ang ◽  
Divya Rawat ◽  
Rahul Khatri ◽  
Thomas Linn
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Graft Function ◽  
Individual Therapy ◽  
Regenerative Therapy ◽  
Pancreatic Islet Transplantation

Type 1 diabetes is an autoimmune disease resulting in the permanent destruction of pancreatic islets. Islet transplantation to portal vein provides an approach to compensate for loss of insulin producing cells. Clinical trials demonstrated that even partial islet graft function reduces severe hypoglycemic events in patients. However, therapeutic impact is restrained due to shortage of pancreas organ donors and instant inflammation occurring in the hepatic environment of the graft. We summarize on what is known about regenerative therapy in type 1 diabetes focusing on pancreatic islet transplantation and new avenues of cell substitution. Metabolic pathways and energy production of transplanted cells are required to be balanced and protection from inflammation in their intravascular bed is desired. Mesenchymal stem cells (MSCs) have anti-inflammatory features, and so they are interesting as a therapy for type 1 diabetes. Recently, they were reported to reduce hyperglycemia in diabetic rodents, and they were even discussed as being turned into endodermal or pancreatic progenitor cells. MSCs are recognized to meet the demand of an individual therapy not raising the concerns of embryonic or induced pluripotent stem cells for therapy.

Stem cell-based approaches to solving the problem of tissue supply for islet transplantation in type 1 diabetes

2004 ◽  
Vol 36 (4) ◽  
pp. 667-683 ◽  
Author(s):  
Cale N Street ◽  
Simonetta Sipione ◽  
Lisa Helms ◽  
Tanya Binette ◽  
Ray V Rajotte ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Islet Transplantation
Sign in / Sign up

Export Citation Format

Share Document